Purple Biotech (PPBT) Operating Expenses (2014 - 2026)

Purple Biotech (PPBT) has 12 years of Operating Expenses data on file, last reported at $2.3 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 60.1% year-over-year to $2.3 million in Q1 2026; TTM through Mar 2026 was $7.8 million, a 0.09% change from a year earlier, with the FY2025 full-year figure at $27.5 million, up 149.5% from the prior year.
• Operating Expenses for Q1 2026 stood at $2.3 million, down from $3.0 million in the prior quarter.
• Over the last five years, Operating Expenses for PPBT reached as high as $7.3 million in Q1 2022 and fell as low as $1.0 million in Q4 2024.
• Historically, Operating Expenses has averaged $3.8 million across 5 years, with a median of $3.6 million in 2022.
• Across the five-year window, Operating Expenses sank 83.79% in 2024 and soared 191.73% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $6.6 million in 2022, then decreased by 5.06% to $6.3 million in 2023, then sank by 83.79% to $1.0 million in 2024, then surged by 191.73% to $3.0 million in 2025, then fell by 24.06% to $2.3 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $2.3 million in Q1 2026, $3.0 million in Q4 2025, and $1.4 million in Q3 2025.